Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00996892 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors

A Phase 1 study, sponsored by Genentech.

Terminated
Registry status
Phase 1
Development phase
178
Enrollment target

NCT00996892: Clinical Trial Phase 1 study, sponsored by Genentech.

NCT00996892 is a Phase 1 study that was terminated before completion, run by Genentech. The registered enrollment target is 178 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (197% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00996892, a Phase 1 study, was terminated before completion, sponsored by Genentech.

TERMINATED
Registry status
Phase 1
Development phase
178 participants
Enrollment target

Study Summary

This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.

Primary Outcome

DLT was defined as 1 of the following toxicities considered treatment related by Investigator: Grade ≥3 non-hematologic, non-hepatic organ toxicity, excluding the following: Grade 3 nausea, vomiting, or diarrhea that resolved to Grade ≤1 within 7 days, Grade 3 rash or Grade ≥3 fatigue that resolved to Grade ≤2 within 7 days, Grade ≥3 hyperglycemia or lipid profile results that occurred during non-fasting conditions, Grade 3 or 4 elevation of serum creatine phosphokinase levels or Grade 3 non cli

Interventions

  • DRUG Cobimetinib
  • DRUG Pictilisib

Trial Details

FieldValue
Enrollment Target 178 participants
Start Date 2009-11
Est. Completion 2014-03
Phase Phase 1
Genentech

332 total trials

Why NCT00996892 stopped before completion

NCT00996892 is an interventional study that assigns participants to a tested intervention. The registered 178 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (197% higher).

The record links to 0 conditions, and to 2 interventions - of which Cobimetinib is the first listed.

NCT00996892 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00996892 about?

NCT00996892 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors". This is an open-label, multicenter, Phase Ib dose-escalation study designed to assess the safety, tolerability and pharmacokinetics of oral dosing of cobimetinib and pictilisib administered in combination in patients with locally advanced or metastatic solid tumors.

What is the current status of trial NCT00996892?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 178 participants. The study started on 2009-11. Estimated completion is 2014-03.

What interventions are being tested in trial NCT00996892?

The interventions under investigation include: Cobimetinib (DRUG), Pictilisib (DRUG).

Who is sponsoring clinical trial NCT00996892?

This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00996892's enrollment target sits among peer trials

178 311th of 2000 higher than 1,688 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03642002 · 178 participants · NA

    The Effects of Music Therapy on Adult Patients Requiring Mechanical Ventilation in the ICU

  • NCT04227847 · 178 participants · Phase 1

    A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

  • NCT04855214 · 178 participants

    Evaluating the Experience of Upper Limb Prosthesis Use

  • NCT05391126 · 178 participants · NA

    GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00996892, the US trial registry maintained by the National Library of Medicine. NCT00996892 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.